Predicting pediatric age-matched weight and body mass index

AAPS Journal

Volumn 16, Issue 6, 2014, Pages 1372-1379

  Sy, Sherwin K B ^a   Asin Prieto, Eduardo ^a   Derendorf, Hartmut ^a   Samara, Emil ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b PharmaPolaris International   (United States)

Author keywords

Age; Allometry; BMI; Pediatric; Weight

Indexed keywords

TENOFOVIR; ADENINE; PHOSPHONIC ACID DERIVATIVE;

ALLOMETRY; ARTICLE; BODY MASS; BODY WEIGHT; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG RESEARCH; PEDIATRICS; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; SIMULATION; STANDARDIZATION; STATISTICAL ANALYSIS; VOLUME OF DISTRIBUTION; WORLD HEALTH ORGANIZATION; ADOLESCENT; AGING; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; CHILD; COMPUTER SIMULATION; FEMALE; HUMAN; INFANT; MALE; NEWBORN; PHYSIOLOGY; PREDICTIVE VALUE; PRESCHOOL CHILD; SOFTWARE; STATISTICAL MODEL;

ADENINE; ADOLESCENT; AGING; BODY MASS INDEX; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; ORGANOPHOSPHONATES; PREDICTIVE VALUE OF TESTS; SOFTWARE; TENOFOVIR;

EID: 84919664798     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9657-9     Document Type: Article

References (23)

1. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276(5309):122–6.
2. Hu TM, Hayton WL. Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci. 2001;3(4):E29. doi:10.1208/ps030429.
3. Savage VM, Gillooly J, Woodruff W, West G, Allen A, Enquist B, et al. The predominance of quarter‐power scaling in biology. Funct Ecol. 2004;18(2):257–82.
4. Nagilla R, Ward KW. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci. 2004;93(10):2522–34. doi:10.1002/jps.20169.
5. Mahmood I. Prediction ofdrugclearancein childrenfrom adults: a comparison of several allometric methods. Br J Clin Pharmacol. 2006; 61(5):545–57. doi:10.1111/j.13652125.2006.02622.x.
6. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm. 1982;10(2):201–27.
7. Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev. 1984;15(5–6):1071–121. doi:10.3109/03602538409033558.
8. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30(5):329–32.
9. Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther Drug Monit. 2007;29(3):271–8. doi:10.1097/FTD.0b013e318042d3c4.
10. Cella M, Knibbe C, Danhof M, Della Pasqua O. What is the right dose for children? Br J Clin Pharmacol. 2010;70(4):597–603.
11. Poggesi I, Benedetti MS, Whomsley R, Le Lamer S, Molimard M, Watelet JB. Pharmacokinetics in special populations. Drug Metab Rev. 2009;41(3):422–54. doi:10.1080/10837450902891527.
12. Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet. 2008;47(4):231–43. doi:10.2165/00003088200847040-00002.
13. Chatelut E. Population approaches in paediatrics. Fundam Clin Pharmacol. 2008;22(6):575–8. doi:10.1111/j.14728206.2008.00647.x.
14. Holford N. Dosing in children. Clin Pharmacol Ther. 2010;87(3):367–70. doi:10.1038/clpt.2009.262.
15. Sumpter AL, Holford NH. Predicting weight using postmenstrual age–neonates to adults. Paediatr Anaesth. 2011;21(3):309–15. doi:10.1111/j.1460-9592.2011.03534.x.
16. WHO. Working Group on Infant Growth. An evaluation of infant growth. Geneva: World Health Organization; 1994.
17. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. CDC growth charts for the United States: methods and development. Vital Health Stat. 2002;11(246):1–190.
18. Victora CG, Morris SS, Barros FC, de Onis M, Yip R. The NCHSreferenceand the growth ofbreast-and bottle-fedinfants. J Nutr. 1998;128(7):1134–8.
19. Dibley MJ, Goldsby JB, Staehling NW, Trowbridge FL. Development of normalized curves for the international growth reference: historical and technical considerations. Am J Clin Nutr. 1987;46(5):736–48.
20. Growth chart datasets from both the CDC and WHO are downloadable from http://www.cdc.gov/growthcharts/who_charts.htm
21. Bouazza N, Urien S, Hirt D, Frange P, Rey E, Benaboud S, et al. Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients. J Acquir Immune DeficSyndr. 2011;58(3):283–8. doi:10.1097/QAI.0b013e3182302ea8.
22. Sy SK, Innes S, Derendorf H, Cotton MF, Rosenkranz B. Estimation of intracellular concentration of stavudinetriphosphate in HIV-infected children given the reduced dose of 0.5 mg/kg twice daily. Antimicrob Agents Chemother. 2013. doi: 10.1128/AAC.01717-13.
23. Strougo A, Eissing T, Yassen A, Willmann S, Danhof M, Freijer J. First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. J Pharmacokinet Pharmacodyn. 2012;39(2):195–203. doi:10.1007/s10928-012-9241-9.